Loading...
•
Sep 30, 2020
Mimedx Q3 2020 Earnings Report
Achieved strong rebound in sequential sales growth and relisted shares on Nasdaq.
Key Takeaways
MiMedx reported Q3 2020 net sales of $64.3 million. The company achieved several key objectives, including a strong rebound in sequential sales growth, the launch of EpiCord® Expandable, and the relisting of shares on Nasdaq.
Third quarter net sales of $64.3 million.
Adjusted net sales of $63.3 million, excluding impacts of the Company’s transition in revenue recognition.
Net loss of $19.4 million, reflecting $12.0 million of investigation, restatement and other related expenses and $8.2 million loss on extinguishment of debt.
Adjusted EBITDA of $6.9 million.
Forward Guidance
Company expects costs to increase over time as it invests in additional clinical and scientific research, including internal product development, clinical efficacy and economic data, and pre-clinical research supportive of future growth objectives.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...